IPN Ipsen SA

IPSEN: Déclaration des transactions sur actions propres réalisées du 12/12/2016 au 16/12/2016

PARIS--(BUSINESS WIRE)--

Regulatory News:

Présentation agrégée par jour et par marché

Nom de l'émetteur  

Code Identifiant de

l'émetteur

 

Jour de la

transaction

 

Code identifiant de

l'instrument financier

 

Volume total journalier (en

nombre d'actions)

 

Prix pondéré moyen

journalier

d'acquisition des

actions

  Marché
IPSEN   549300M6SGDPB4Z94P11   2016.12.12   FR0010259150   2980   65.73   XPAR
IPSEN 549300M6SGDPB4Z94P11 2016.12.12 FR0010259150 0 NA BATE
IPSEN 549300M6SGDPB4Z94P11 2016.12.12 FR0010259150 92 65.51 CHIX
IPSEN   549300M6SGDPB4Z94P11   2016.12.12   FR0010259150   128   65.51   TRQX
IPSEN 549300M6SGDPB4Z94P11 2016.12.13 FR0010259150 2615 66.06 XPAR
IPSEN 549300M6SGDPB4Z94P11 2016.12.13 FR0010259150 59 66.06 BATE
IPSEN 549300M6SGDPB4Z94P11 2016.12.13 FR0010259150 350 66.06 CHIX
IPSEN   549300M6SGDPB4Z94P11   2016.12.13   FR0010259150   176   66.06   TRQX
IPSEN 549300M6SGDPB4Z94P11 2016.12.14 FR0010259150 3200 65.47 XPAR
IPSEN 549300M6SGDPB4Z94P11 2016.12.14 FR0010259150 0 NA BATE
IPSEN 549300M6SGDPB4Z94P11 2016.12.14 FR0010259150 0 NA CHIX
IPSEN   549300M6SGDPB4Z94P11   2016.12.14   FR0010259150   150   65.00   TRQX
IPSEN 549300M6SGDPB4Z94P11 2016.12.15 FR0010259150 2007 67.22 XPAR
IPSEN 549300M6SGDPB4Z94P11 2016.12.15 FR0010259150 0 NA BATE
IPSEN 549300M6SGDPB4Z94P11 2016.12.15 FR0010259150 0 NA CHIX
IPSEN   549300M6SGDPB4Z94P11   2016.12.15   FR0010259150   0   NA   TRQX
IPSEN 549300M6SGDPB4Z94P11 2016.12.16 FR0010259150 3045 67.98 XPAR
IPSEN 549300M6SGDPB4Z94P11 2016.12.16 FR0010259150 16 68.01 BATE
IPSEN 549300M6SGDPB4Z94P11 2016.12.16 FR0010259150 92 68.01 CHIX
IPSEN   549300M6SGDPB4Z94P11   2016.12.16   FR0010259150   47   68.01   TRQX

L'information détaillée transaction par transaction des opérations réalisées ainsi que les objectifs de rachat sont disponibles sur le site internet de la société à l'adresse suivante: http://www.ipsen.com/fr/investisseurs/information-reglementee/

FR
20/12/2016

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

Konrad Zomer
  • Konrad Zomer
AKRBF AKER BP ASA
LR LEGRAND
REL RELX PLC
FP TOTAL SE
HEIA HEINEKEN NV
IPN IPSEN SA
TKA THYSSENKRUPP AG
UBSN UBS GROUP AG
CBK COMMERZBANK AG
DAI DAIMLER AG
RXL REXEL SA
SCMN SWISSCOM AG
FHZN FLUGHAFEN ZURICH AG
EL ESSILORLUXOTTICA SA
SCHP SCHINDLER HOLDING AG PREF
DTE DEUTSCHE TELEKOM AG
MOCORP METSO OUTOTEC OYJ
STR STRABAG SE
NN NN GROUP N.V.
ABI ANHEUSER-BUSCH INBEV SA/NV
SIE SIEMENS AG
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
ADYEN ADYEN NV
ENR SIEMENS ENERGY AG
DSY DASSAULT SYSTEMES SA
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
H2O HIDROELECTRICA S.A.
CVC CVC CAPITAL PARTNERS PLC
TKMS TKMS AG & CO. KGAA
MICC MAGNUM ICE CREAM COMPANY N.V. (THE)
ULVR UNILEVER PLC
8h / 5m 8h / 5m 1 EN
Konrad Zomer
  • Konrad Zomer
AKRBF AKER BP ASA
LR LEGRAND
REL RELX PLC
FP TOTAL SE
HEIA HEINEKEN NV
IPN IPSEN SA
TKA THYSSENKRUPP AG
UBSN UBS GROUP AG
CBK COMMERZBANK AG
DAI DAIMLER AG
RXL REXEL SA
SCMN SWISSCOM AG
FHZN FLUGHAFEN ZURICH AG
EL ESSILORLUXOTTICA SA
SCHP SCHINDLER HOLDING AG PREF
DTE DEUTSCHE TELEKOM AG
MOCORP METSO OUTOTEC OYJ
STR STRABAG SE
NN NN GROUP N.V.
ABI ANHEUSER-BUSCH INBEV SA/NV
SIE SIEMENS AG
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
ADYEN ADYEN NV
ENR SIEMENS ENERGY AG
DSY DASSAULT SYSTEMES SA
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
H2O HIDROELECTRICA S.A.
CVC CVC CAPITAL PARTNERS PLC
TKMS TKMS AG & CO. KGAA
MICC MAGNUM ICE CREAM COMPANY N.V. (THE)
ULVR UNILEVER PLC
8h / 14m 8h / 14m 1 FR
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
9h / 2m 9h / 2m 1 EN
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
9h / 11m 9h / 11m 1 FR
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen delivers strong results in 2025, driven by solid execution acros...

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points2025 continued pipel...

11h / 49m 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch